The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Atherosclerosis Drugs Market Progress Between 2026 And 2030?
The market size for atherosclerosis drugs has experienced steady growth in recent years. It is anticipated to expand from $50.91 billion in 2025 to $52.45 billion in 2026, reflecting a compound annual growth rate (CAGR) of 3.0%. This historical growth can be ascribed to the increasing prevalence of cardiovascular diseases, heightened awareness concerning heart health, the widespread adoption of statins and other cholesterol-lowering medications, government initiatives aimed at cardiovascular care, and the expansion of hospital and retail pharmacy infrastructure.
The atherosclerosis drugs market size is anticipated to demonstrate consistent growth over the coming years, with expectations to reach $61.19 billion by 2030, progressing at a compound annual growth rate (CAGR) of 3.9%. This expansion during the forecast period is propelled by factors such as the increasing scope of precision medicine within cardiovascular treatment, a greater embrace of digital health monitoring tools, an escalating demand for combination therapies, the expanding geriatric demographic, and breakthroughs in new classes of anti-atherosclerosis drugs. Key trends foreseen for this period include personalized atherosclerosis therapy, the creation of combination drug formulations, support for minimally invasive treatment options, a strong emphasis on preventive cardiovascular healthcare, and improved patient adherence coupled with digital monitoring.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp
Which Drivers Are Supporting The Atherosclerosis Drugs Market Growth?
The widespread occurrence of cardiovascular diseases is projected to drive the growth of the atherosclerosis drug market. Cardiovascular diseases refer to conditions affecting the heart and blood vessels, while atherosclerosis involves the buildup of fats, cholesterol, and other substances on a person’s artery walls. This accumulation of plaque within arteries, a hallmark of atherosclerosis, contributes to cardiovascular diseases such as coronary heart disease and stroke. Atherosclerosis drugs are utilized to treat cardiovascular diseases by reducing the potential for complications and managing underlying factors like increased cholesterol levels and blood clot formation. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the prevalence of cardiovascular diseases will stimulate the atherosclerosis drug market.
Which Segment Categories Are Included In The Atherosclerosis Drugs Market Segment Analysis?
The atherosclerosis drugs market covered in this report is segmented –
1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors
Which Trends Are Shaping The Atherosclerosis Drugs Market?
Major companies in the atherosclerosis drugs market are developing new products, such as anti-inflammatory drugs, to enhance their profitability. Atherosclerosis anti-inflammatory drugs are treatments designed to reduce inflammation associated with atherosclerosis, a condition marked by plaque accumulation in arteries. For instance, AGEPHA Pharma, a Europe-based medical product manufacturer, launched LODOCO in June 2023. The U.S. FDA granted approval to LODOCO (colchicine, 0.5 mg tablet) as the first anti-inflammatory atheroprotective cardiovascular treatment. This drug has demonstrated efficacy in lowering the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. LODOCO addresses residual inflammation, which is a key factor in atherosclerotic cardiovascular disease (ASCVD). Approved for use either alone or alongside cholesterol-lowering medications, this drug represents a significant breakthrough in cardiovascular care.
Who Are The Active Companies Shaping The Atherosclerosis Drugs Market?
Major companies operating in the atherosclerosis drugs market are Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc.
Get The Full Atherosclerosis Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report
Which Region Represents The Largest Share Of The Atherosclerosis Drugs Market?
North America was the largest region in the atherosclerosis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Atherosclerosis Drugs Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report
Browse Through More Reports Similar to the Global Atherosclerosis Drugs Market 2026, By The Business Research Company
Atherosclerosis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report
Cardiovascular Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
Atorvastatin Market Report 2026
https://www.thebusinessresearchcompany.com/report/atorvastatin-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model